Food and Drug Administration
January 13, 2003
Slides
Fabrazyme® (agalsidase beta)
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Fabrazyme® (agalsidase beta), Alison Lawton, Regulatory Affairs & Quality Systems (HTM) (PPT)
Fabrazyme® Recombinant Human aGalactosidase, Genzyme, Corp. Introduction, FDA (HTM) (PPT)
Genzyme Marketing Application STN 103979/0 Recombinant Human a-Galactosidase for treatment of Fabry Disease (HTM) (PPT)